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Background: An intimidating challenge to transporting drugs into the brain parenchyma is 
the presence of the blood–brain barrier (BBB). Glucose is an essential nutritional substance 
for brain function sustenance, which cannot be synthesized by the brain. Its transport primar-
ily depends on the glucose transporters on the brain capillary endothelial cells. In this paper, 
the brain-targeted properties of glucose-modified liposomes using polyethylene glycols with 
different chain lengths as the linkers were compared and evaluated to establish an optimized 
drug-delivery system.
Methods: Coumarin 6-loaded liposomes (GLU200-LIP, GLU400-LIP, GLU1000-LIP, and 
GLU2000-LIP) composed of phospholipids and glucose-derived cholesterols were prepared 
by thin-film dispersion-ultrasound method. The BBB model in vitro was developed to evaluate 
the transendothelial ability of the different liposomes crossing the BBB. The biodistribution of 
liposomes in the mice brains was identified by in vivo and ex vivo nearinfrared fluorescence 
imaging and confocal laser scanning microscopy and further analyzed quantitatively by high-
performance liquid chromatography.
Results: Glucose-derived cholesterols were synthesized and identified, and coumarin 6-loaded 
liposomes were prepared successfully. The particle sizes of the four types of glucose-modified 
liposomes were around or smaller than 100 nm with a polydispersity index less than 0.300. 
GLU400-LIP, GLU1000-LIP, and GLU2000-LIP achieved higher cumulative cleared volumes 
on BBB model in vitro after 6 hours compared with GLU200-LIP (P < 0.05) and were signifi-
cantly higher than that of the conventional liposome (P < 0.001). The qualitative and quantitative 
biodistribution results in the mice showed that the accumulation of GLU1000-LIP in the brain 
was the highest among all the groups (P < 0.01 versus LIP).
Conclusion: The data indicated that GLU400-LIP, GLU1000-LIP, and GLU2000-LIP all pos-
sess the potential of brain targeting, among which GLU1000-LIP, as a promising drug-delivery 
system, exhibited the strongest brain delivery capacity.
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Introduction
Some of the most dangerous threats to health are seen in the dramatic increase in 
incidence and low recovery rate for central nervous system (CNS) diseases such as 
brain tumor, epilepsy, Alzheimer disease, Parkinson’s disease, and neurodegenerative 
disorders. The presence of the blood–brain barrier (BBB) is a prohibitive obstacle to 
transporting drugs into the brain parenchyma. Only 2% of small molecules can pass the 
BBB through paracellular or transcellular pathways, while the take-up of most of the 
small molecules and all of the large molecules is prevented by the BBB.1,2 Many drugs 
are unable to reach the action site with an adequate amount in clinical practice because 
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of the BBB. Accordingly, the development of   brain-targeted 
drug-delivery systems is imperative.
The unique functional structure of the BBB is composed 
of brain capillary endothelial cells (BCECs), astrocytes 
(ACs), and the basement membrane between BCECs and 
ACs. The BBB helps to maintain homeostasis in the brain, 
and tight junctions exist between BCECs.3 The structural 
property of the BBB guarantees against the uptake of both 
harmful substances and therapeutic drugs into the brain 
parenchyma. Briefly, the BBB not only plays an important 
role in protecting the brain, but also inhibits drugs from 
reaching the action site in the brain.4
One pathway for substances to cross the BBB is by 
carrier-mediated transport. The tight junctions effectively 
switch on BCECs, and the endothelial cells are required to 
maintain a high level of expression of transporters for essen-
tial polar metabolites to facilitate their entry into the brain, 
such as glucose and amino acids.5 The expressions of these 
carriers were often polarized to optimize substrates (endog-
enous substances and nutrients) transporting into the brain. 
Several carrier systems have been described   previously, 
including those specifically designed with small-molecule 
peptides, hexoses, monocarboxylic acids, amino acids, 
organic anions, and cations.6–9 Full utilization of these carrier 
systems expressed on the BBB may be an attractive strategy 
for therapeutic delivery of drugs that otherwise have minimal 
access to the CNS.
One example of carrier-mediated transporter is hexose 
transporters, especially glucose transporters (GLUTs). The 
brain cannot synthesize or store glucose by itself; therefore 
the glucose transporters are responsible for transporting 
  glucose into or out of the brain internal environment to 
sustain the cerebral function. A family of GLUT isoforms 
named GLUT1–7 have been gradually discovered.10,11 
GLUT1 and GLUT3 are predominant GLUTs on the human 
BBB. GLUT1 is highly expressed on the membrane of 
BCECs and responsible for stereoselectively transporting 
the D-glucose enantiomer into the extracellular space of 
the brain.12,13 GLUT3 is the major neuronal GLUT and 
helps transport glucose from the extracellular space into 
the neurons.14 In addition, GLUT2 is expressed on the 
ACs of the brain. Since GLUTs can facilitate the glucose 
transport from the blood to the brain, glucose analogs 
should be good candidates for drug transport through the 
BBB.15,16 In previous studies, different glycol-conjugates 
as candidates for the treatment of CNS diseases have 
been synthesized, which could increase BBB permeability 
through the affinity with GLUT1, such as dopamine,17,18 
glycosyl-derivatives of ibuprofen,19 among others. 
Besides the prodrugs, glucose-modified liposomes using 
ethylene glycols with short chain length as the linkers have 
also been investigated.20
Polyethylene glycol (PEG)-modified liposomes with 
long-circulating characteristics are successfully applicable 
for many delayed and controlled formulations research. The 
liposomes modified by PEGs can prevent themselves from 
getting trapped by the reticuloendothelial system (RES) such 
as liver and spleen.21
PEGs with longer chain length may decrease the 
brain-targeted efficiency of the liposome because of the 
steric hindrance, while PEGs with shorter chain length 
may obstruct the exposure of the glucose. In order to 
explore their difference and determine the optimal length 
of PEG for drug delivery in this study, the character-
istics of glucose-modified liposomes using PEGs with 
different chain lengths as the linkers were compared 
and evaluated both in vitro and in vivo, thus developing 
the optimal brain-targeting drug-delivery system with a 
strong transendothelial ability crossing the BBB. Glucose 
residue-linked cholesterol via PEGs with different chain 
lengths at the C-6 position of the glucose were synthe-
sized, which may theoretically attain high affinity with 
GLUT1. The glucose-modified liposomes were prepared 
with these glucose-linked cholesterol derivates. In addition, 
the brain-delivery properties of these new drug-delivery 
systems were illustrated in vitro and in vivo. Finally, the 
brain distribution characteristics of these glucose-modified 
liposomes were also investigated.
Materials and methods
Reagents and chemicals
Soybean phospholipids and cholesterol (CHO) were 
purchased from Bio Life Science and Technology Co, 
Ltd (Shanghai, People’s Republic of China). Coumarin 6 
was purchased from Sigma-Aldrich (St Louis, MO). 1,1′-
dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine 
(DIR) was purchased from Biotium (Hayward, CA). Other 
chemicals were obtained from commercial sources of 
analytical grade.
Animals
Kunming mice were purchased from the Experimental 
Animal Center of Sichuan University (Sichuan, People’s 
Republic of China). All animal procedures for this study 
were approved by the Experiment Animal Administrative 
Committee of Sichuan University.
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Synthesis of CHO-PEg200-gLU,  
CHO-PEg400-gLU, CHO-PEg1000-gLU, 
and CHO-PEg2000-gLU
The potential ligands La–Ld were synthesized as outlined 
in Scheme 1. These ligands possess bifunctional   properties: 
a lipophilic steriod for the insertion into the liposomal 
membrane and a hydrophilic glucose residue outside the 
membrane for the recognition of GLUT1. The cholesterol 
links glucose residue via PEGs with different chain lengths 
(PEG200, PEG400, PEG1000, and PEG2000) at the C-6 
position of the glucose. PEGs with adequate space length 
could leave the glycosyl group at the liposome surface and 
provide good anchors for biological receptors and ligands, 
reducing the nonspecific binding of proteins and other bioac-
tive molecules.
Synthesis of the compound 2
To the solution of cholesterol (100 g, 260 mmol) in 300 mL 
dry pyridine, paratoluensulfonyl chloride (74 g, 400 mmol) 
was added at 0°C. The reaction mixture was stirred at 50°C 
overnight, and then concentrated in vacuum to form resi-
due. The residue was partitioned with ether and water (1:1 
v/v). The aqueous layer was then extracted with ether. The 
combined organic layer was dried on anhydrous magnesium 
sulfate and concentrated. The crude product was recrystal-
lized in petrol ether to afford a white solid (116 g, 83%), and 
the melting point was 132°C–133°C.
Synthesis of the compound 3
The prepared cholesteryl tosylate 2 (100 g, 185 mmol) was 
refluxed for 5 hours with tetraoxatetradecane diol (176 g, 
740 mmol) in 350 mL dry dioxane. The insolubles were 
removed by filtration. The filtrate was concentrated in 
vacuum, and the residue was redissolved in dichloromethane, 
washed with brine, dried over anhydrous magnesium   sulfate, 
and concentrated on a rotary evaporator. The residue was 
purified on a silica-gel chromatography column to get product 
3 (44.8 g, 43%).
Synthesis of the compound 4
To a solution of alcohol 3 (30 g, 53.4 mmol) and   triethylamine 
(27 g, 267 mmol) in tetrahydrofuran (THF) in ice bath, 
methanesulfonyl chloride (7.9, 69.4 mmol) was added. After 
10 minutes, the solution was warmed to room temperature 
and further stirred for 4 hours, and the reaction mixture was 
concentrated. The residue was partitioned with ethyl acetate 
and water. The aqueous layer was then extracted with ethyl 
acetate. The combined organic layer was dried on anhydrous 
magnesium sulfate and concentrated. The crude product was 
purified on a silica-gel chromatography column to get 4 as 
yellow oil (31.4 g, 92%).
general procedure for the preparation of compound 5
A solution of 4 (1 equiv) in THF was added dropwise 
to a slurry of NaH (2 equiv) in THF, and stirred for 
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Scheme 1 Reagents and conditions: (a) TsCl, pyridine, 50°C, overnight; (b) HOCH  2(CH2OCH2)3 CH2OH, dioxane, reflux, 8 hours; (c) MsCl, Et3 N, THF, rt, 4 hours; 
(d) PEGs (PEG200, PEG400, PEG1000, PEG2000), NaH, THF, reflux, overnight; (e) succinic anhydride, pyridine, 75°C, 8 hours; (f) DCC, DMAP, 1,2,3,4-tetra-O-trimethylsilyl-
D-glucopyranose, dichloromethane, rt, overnight; (g) TFA, THF, rt, 1 hour.
Abbreviations: TsCl, 4-toluenesulfonyl chloride; THF, tetrahydrofuran; DCC, dicyclohexylcarbodiimide; DMAP, 4-dimethylaminopyridine; TFA, trifluoroacetic acid.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
165
Glucose-modified liposomes using polyethylene glycols as linkers for brain targetingInternational Journal of Nanomedicine 2012:7
another 30 minutes. The PEGs (2 equiv) in THF was dropped 
in the mixture and refluxed overnight, and then the water 
was carefully quenched. The mixture was diluted with 
ethyl acetate and repeatedly washed with brine, dried over 
anhydrous magnesium sulfate, filtered, and evaporated to 
dryness. The crude oil was chromatographically purified 
on a silica column to afford compound 5 as yellow oil: 
5a (2.43 g, 43%), 5b (2.87 g, 39%), 5c (4.07 g, 41%), and 
5d (7.39 g, 38%).
general procedure for the preparation  
of compound 6
To a solution of 5 (1 equiv) in pyridine was added succinic 
anhydride (1.5 equiv). This mixture was stirred at 75°C 
for 8 hours, and then was concentrated. The residue was 
partitioned with ethyl acetate and water. The organic layer 
was washed with water, dried on anhydrous magnesium 
sulfate, and concentrated. The crude product was purified on 
a silica-gel chromatography column to get acid 6 as yellow 
oil: 6a (1.21 g, 74%), 6b (1.63 g, 81%), 6c (3.01 g, 76%), 
and 6d (4.19 g, 64%).
general procedure for the preparation  
of compound 7
A stirred solution of acid 6 (1 equiv) in dry CH2Cl2 
was treated with 1,2,3,4 -tetra-O-(trimethylsilyl)-d-
  glucopyranose (1.1 equiv),21 dicyclohexylcarbodiimide 
(DCC) (1.2 equiv) and 4-dimethylaminopyridine (DMAP) 
(0.1 equiv). The mixture was kept at room temperature over-
night and then filtered. The filtrate was concentrated and the 
residue was purified by flash chromatography to yield 7 as 
oil: 7a (528 mg, 61%), 7b (672 mg, 66%), 7c (711 mg, 52%), 
7d (803 mg, 42%).
general procedure for the preparation  
of compound L
The compound 7 (1 equiv) in 30 mL tetrahydrofuran was 
treated with trifluoracetic acid (0.1 equiv) for 1 hour at room 
temperature and then solid sodium carbonate (0.1 equiv) was 
added. The reaction mixture was filtered and concentrated. 
The residue was purified by flash chromatography to give 
L as oil.
La (492 mg, 82%), IR (KBr): 3471, 2972, 2938, 1753, 
1252, 1114 cm−1,  1H NMR (400 MHz, CDCl3, δ ppm): 
5.33 (m, 1H, chol H-6), 5.27 (m, 1H, H-1), 4.82 (m, 1H, 
H-6), 4.39 (m, 1H, H-2), 4.26 (m, 1H, H-5), 3.99 (m, 1H, 
H-4), 3.72–3.68 (m, PEG200-H and 4 × CH2CH2O), 3.54 
(m, 1H, H-3), 3.27 (m, 1H, H-6′), 3.18 (m, 1H, chol H-3), 
2.67 (m, 4H, COCH2CH2CO), 2.37–0.66 (remaining chol 
protons) with 0.66 (s, 3H, CH3-18), 0.85 (d, 6H, CH3-26, 
CH3-27, J = 6.7 Hz), 0.91 (d, 3H, CH3-21, J = 6.8 Hz), 0.99 
(s, 3H, CH3-19)
Lb (631 mg, 73%), IR (KBr): 3472, 2972, 2937, 1751, 
1251, 1111 cm−1,  1H NMR (400 MHz, CDCl3, δ ppm): 
5.33 (m, 1H, chol H-6), 5.25 (m, 1H, H-1), 4.80 (m, 1H, 
H-6), 4.40 (m, 1H, H-2), 4.25 (m, 1H, H-5), 4.01 (m, 1H, 
H-4), 3.72–3.63 (m, PEG400-H and 4 × CH2CH2O), 3.52 
(m, 1H, H-3), 3.35 (m, 1H, H-6′), 3.18 (m, 1H, chol H-3), 
2.68 (m, 4H, COCH2CH2CO), 2.37–0.67 (remaining chol 
protons) with 0.67 (s, 3H, CH3-18), 0.86 (d, 6H, CH3-26, 
CH3-27, J = 6.7 Hz), 0.91 (d, 3H, CH3-21, J = 6.8 Hz), 0.99 
(s, 3H, CH3-19)
Lc (825 mg, 76%), IR (KBr): 3473, 2975, 2935, 1750, 
1253, 1109 cm−1,  1H NMR (400 MHz, CDCl3, δ ppm): 
5.32 (m, 1H, chol H-6), 5.24 (m, 1H, H-1), 4.58 (m, 1H, 
H-6), 4.39 (m, 1H, H-2), 4.32 (m, 1H, H-5), 3.99 (m, 1H, 
H-4), 3.73–3.55 (m, PEG800-H and 4 × CH2CH2O), 3.48 
(m, 1H, H-3), 3.34 (m, 1H, H-6′), 3.15 (m, 1H, chol H-3), 
2.69 (m, 4H, COCH2CH2CO), 2.37–0.66 (remaining chol 
protons) with 0.66 (s, 3H, CH3–18), 0.86 (d, 6H, CH3-26, 
CH3-27, J = 6.7 Hz), 0.91 (d, 3H, CH3-21, J = 6.7 Hz), 0.99 
(s, 3H, CH3-19)
Ld (108 mg, 51%), IR (KBr): 3471, 2971, 2934, 1750, 
1249, 1112 cm−1,  1H NMR (400 MHz, CDCl3, δ ppm): 
5.24 (m, 1H, chol H-6), 5.20 (m, 1H, H-1), 4.91 (m, 1H, 
H-6), 4.50 (m, 1H, H-2), 4.21 (m, 1H, H-5), 4.15 (m, 1H, 
H-4), 3.74–3.36 (m, PEG2000-H and 4 × CH2CH2O), 3.33 
(m, 1H, H-3), 3.28 (m, 1H, H-6′), 3.08 (m, 1H, chol H-3), 
2.57 (m, 4H, COCH2CH2CO), 2.28–0.58 (remaining chol 
protons) with 0.58 (s, 3H, CH3-18), 0.76 (d, 6H, CH3-26, 
CH3-27, J = 6.7 Hz), 0.81 (d, 3H, CH3-21, J = 6.8 Hz), 0.93 
(s, 3H, CH3-19)
Preparation of liposomes
Glucose-modified liposomes (GLU200-LIP, GLU400-LIP, 
GLU1000-LIP, and GLU2000-LIP) loaded with coumarin 6 
were prepared by the lipid film hydration-ultrasound method 
with cholesterols modified with PEG linkers of different 
lengths. Briefly, lipid materials (the molar ratio of phos-
pholipid and cholesterol derivatives was 2:1) and coumarin 
6 were dissolved in chloroform, and then chloroform was 
removed by vacuum evaporation on a rotary evaporator. 
The uniform thin film was kept under vacuum to remove 
the organic solvent completely. The lipid film was then 
incubated in tris-EDTA buffered saline (10 mM tris, 2 mM 
EDTA; pH 7.4) for 1 hour at 37°C with constant mixing. 
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Subsequently it was further intermittently sonicated by a 
probe sonicator at 80 W for 50 seconds. The final lipid con-
centration was 7.1 µmol/mL, while the final concentration 
of coumarin 6 was 4.8 µg/mL.
Conventional liposomes were evaluated as the control 
in this study. Liposome suspensions were diluted with 
tris-EDTA buffered saline, and the average diameters, 
polydispersity indices (PDI) and zeta-potentials of LIP, 
GLU200-LIP, GLU400-LIP, GLU1000-LIP, and GLU2000-
LIP were determined by Malvern Zetasizer Nano ZS90 
(Malvern Instruments Ltd, Malvern, UK) utilizing dynamic 
light scattering.
Nearinfrared (NIR) fluorescence probe DIR-loaded lipo-
somes employed in the in vivo and ex vivo optical imaging 
studies were prepared by the method described above, with 
the probe replaced by DIR. The final concentration of DIR 
was 20 µg/mL.
Stability of coumarin 6-loaded liposomes 
in the presence of fetal bovine serum
LIP, GLU200-LIP, GLU400-LIP, GLU1000-LIP, and 
GLU2000-LIP were prepared as described above. One 
hundred microliters of the liposomes were separately mixed 
with 1 mL phosphate-buffered saline containing 10% (v/v) 
fetal bovine serum (FBS) respectively, and the mixtures were 
kept at 37°C with constant slight mixing for 24 hours. The 
transmittance of each sample was detected at different time 
points at the wavelength of 750 nm. The variation curves 
were delineated to investigate the stability of LIP, GLU200-
LIP, GLU400-LIP, GLU1000-LIP, and GLU2000-LIP.
Transendothelial ability of coumarin 
6-loaded liposomes on an in vitro  
BBB model
Establishment of the BBB model in vitro
In the study, the BBB model in vitro was established by 
coculturing BCECs and ACs. The coculture model has 
been widely employed in many brain-targeted studies and 
the culture process of BCECs and ACs has been described 
previously.22,23 After a series of purification, the morpholo-
gies of the ACs and BCECs were characterized by inverted 
fluorescence microscopy. BCECs and ACs were cocultured 
in a “contact through feet” model.24,25 Microporous Transwell 
membranes with a pore diameter of 1 µm were inserted in a 
24-well plate and turned upside down, and the ACs at the sec-
ond passage were cultured on the bottom side of the micropo-
rous Transwell membranes at a density of 5 × 105 cells/mL. 
After allowing the ACs to attach for 4 hours, the plate was 
turned over. The complete culture medium for ACs con-
taining 20% FBS was added into the wells.   Approximately 
5 days later, BCECs at the third or fourth passage were 
seeded onto the intramembrane of the inserts at a density 
of 2.5 × 105 cells/mL. The complete culture medium for 
BCECs containing 20% FBS was added to the upper side of 
the   membranes. After 5–7 days of coculturing, the transen-
dothelial electric resistance (TEER) value of the cells was 
measured by a Millicell ERS (Millipore, Bedford, MA).
The fluorescein sodium leakage test  
of the BBB model in vitro
The primarily cultured AC was inoculated on the bottom side 
of microporous Transwell membranes which were inserted 
in a 24-well plate. After reaching confluence under 37°C in 
5% CO2, Ringer-HEPES buffer (150 mM NaCl, 5.2 mM KCl, 
2.2 mM CaCl2, 0.2 mM MgCl2, 6 mM NaHCO3, 2.8 mM 
glucose, and 5 mM HEPES; pH 7.4) was added to the accep-
tor chambers of the 24-well plate (1 mL/well) to replace the 
AC culture medium, and then 200 µL of 2 µg/mL fluores-
cein sodium solution was added to the donor   chambers. The 
solution in the acceptor chambers was removed to determine 
the fluorescence values at predetermined time points, and 
fresh Ringer-HEPES buffer was supplemented for the next 
measurement.
The same treatment was applied on the BCECs monolayer 
cells that were inoculated on the top side of microporous 
Transwell membranes for the BBB model in vitro. The blank 
inserts were employed as controls. Triplicate samples were 
performed. Results were expressed as leakage ratio, which 
further verified the roles of BCECs or ACs in the BBB 
construction and the reliability of the BBB model for the 
transendothelial experiment.
Transendothelial ability of coumarin 6-loaded 
liposomes on an in vitro BBB model
The transport study was performed as described previously.19 
After the establishment of the BBB model in vitro, Ringer-
HEPES buffer was added to the acceptor chambers of the 
24-well plate (1 mL/well) and incubated for 15 minutes under 
37°C in 5% CO2. And then 200 µL of coumarin 6-loaded 
liposomes from each group in Ringer-HEPES solution with a 
total lipid concentration of 160 µM were added to the donor 
chambers, respectively. The fluorescence values of coumarin 
6 in the acceptor chambers were measured after incubation 
for 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, and 6 hours 
by a RF-5301 fluorospectrophotometer (Ex = 465 nm, 
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Em = 502 nm; Shimadzu, Kyoto, Japan). Triplicate samples 
were performed, and the results were expressed as cumula-
tive cleared volume to indicate the transendothelial ability 
of coumarin 6-loaded liposomes.22
Biodistribution of the liposomes in vivo
Nearinfrared fluorescence probe DIR imaging  
for in vivo and ex vivo
The in vivo studies were approved by Sichuan University 
Animal Ethical Experimentation Committee according to the 
requirement of the National Act on the Use of Experimental 
Animals (People’s Republic of China).
Whole mice in vivo NIR fluorescence imaging was 
performed 2, 6, and 12 hours, respectively after intra-
venous injection of DIR-loaded liposomes at a dose of 
0.2 mg DIR/kg. Mice were anesthetized and placed into 
an imaging system (Imaging Station IS2000MM; Kodak, 
Rochester, NY) equipped with a band-pass filter at 770 nm 
and a long-pass filter at 830 nm. Images were captured by 
the charge-coupled device camera embedded in the imaging. 
Similarly, in the ex vivo optical imaging study, DIR-loaded 
liposomes were injected intravenously into the mice at a dose 
of 0.2 mg DIR/kg, and after 1 hour the mice were perfused 
from the heart with normal saline and sacrificed. Their whole 
brains were harvested and imaged as described above.
Confocal laser scanning microscopy
Coumarin 6-loaded liposomes were adopted for the confo-
cal laser scanning microscopy (CLSM) study. Mice were 
anesthetized 1 hour after the intravenous injection of the 
liposomes at a dose of 0.1 mg coumarin 6/kg, then were 
perfused with normal saline from the heart and sacrificed. 
The brains were removed and washed in normal saline. The 
samples were kept in a liquid nitrogen container overnight. 
On the next day, sections were cut from coronal plane onto 
a glass slide by a freezing microtome. Two micrograms per 
milliliter of DAPI was dropped onto the glass slides, and 
the glass slides were placed for 5 minutes in darkness. After 
being washed with distilled water, the frozen sections were 
fixed by glycerol. The fluorescent images were captured by 
a Leica TCS SP5 AOBS confocal microscopy system (Leica, 
Solms, Germany).
Quantitative biodistribution study
Fifteen mice were randomly assigned to five groups 
of three mice each, and treated by LIP, GLU200-LIP, 
GLU400-LIP, GLU1000-LIP, and GLU2000-LIP via the 
tail veins respectively at a dose of 0.1 mg/kg of coumarin 6. 
Mice were anesthetized 1 hour after the liposome injection, 
perfused with normal saline in the heart, and sacrificed. 
Subsequently, organs including hearts, livers, spleens, 
lungs, kidneys, and brains were harvested and flushed with 
normal saline to remove the remaining blood.26 All the 
organs were immersed with a triple amount of water and 
subjected to   homogenization. Ten microliters of internal 
standard (coumarin 7) was precisely added into 200 µL 
organ homogenate, and the mixture was extracted with 1 ml 
N-hexane. After centrifugation at 10,000 rpm for 5 minutes, 
the supernatant was collected and dried under an air stream at 
room temperature. Fifty microliters of methanol was added 
into the dry residue followed by vortexing and sonicating, 
and the sample was centrifuged at 12,000 rpm for 10 minutes. 
Twenty microliters of the supernatant was injected into a 
high-performance liquid chromatography (HPLC) system 
for analysis. A reversed-phase HPLC (Alltech, Deerfield, IL) 
system with a Diamonsil C18 column (200 × 4.6 mm, 5 µm) 
was employed for the analysis in which methanol-water 
(92:8) was used as the mobile phase. The flow rate was 
1 mL/min and the column temperature was 35°C. The exci-
tation and emission wavelength of coumarin 6 were 465 nm 
and 502 nm, respectively.
Statistical analysis
SPSS software (v. 11.0; SPSS Inc, Chicago, IL) was applied 
for the statistical analysis. The comparisons between different 
groups were investigated by analysis of variance (ANOVA) 
and unpaired bilateral t-test was performed for the assessment 
of the samples within a group.
Results
Characterization of glucose-modified 
liposomes linked by PEgs of different 
chain lengths
The electron microscope results showed that the liposomes 
(GLU200, GLU400, GLU1000, and GLU2000) all exhibited 
uniform spherical appearance, demonstrating the successful 
formation of the liposomes (data not shown). As shown in 
Table 1, the average diameter of the conventional coumarin 
6-loaded liposome was around 158 nm with a PDI of 0.172, 
while the average particle sizes of the four types of glucose-
modified liposomes were all around or smaller than 100 nm 
with PDIs less than 0.300.
The aggregation characteristics in FBS were investigated 
subsequently. As shown in Figure 1, the transmittance 
of LIP was below 90% after incubation with phosphate-
buffered saline containing 10% (v/v) FBS for 2 hours. 
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Table 1 The size and Zeta-potential of different coumarin 6-loaded liposomes (n = 3)
Molar ratio of lipids Average size 
(nm)
Polydispersity index 
(PDI)
Zeta-potential 
(mV)
LIP PC:cholesterol (2:1) 158.0 ± 7.1 0.172 ± 0.028 −60.4 ± 12.3
gLU200-LIP PC:CHO-PEg200-gLU (2:1) 86.3 ± 5.7 0.270 ± 0.015 −33.3 ± 3.5
gLU400-LIP PC:CHO-PEg400-gLU (2:1) 81.5 ± 6.3 0.252 ± 0.016 −36.2 ± 2.6
gLU1000-LIP PC:CHO-PEg1000-gLU (2:1) 100.0 ± 5.0 0.265 ± 0.032 −24.9 ± 2.8
gLU2000-LIP PC:CHO-PEg2000-gLU (2:1) 104.9 ± 8.7 0.289 ± 0.013 −20.9 ± 2.4
Abbreviations: LIP, liposomes; gLU, glucose; PC, phospholipid; CHO, cholesterol.
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Figure 2 Fluorescein sodium leakage test of the ACs, BCECs, and the BBB model 
in vitro. The blank inserts were employed as controls (n = 3).
Abbreviations:  ACs,  astrocytes;  blood–brain  barrier;  BCECs,  brain  capillary 
endothelial cells.
Compared with LIP, the transmittances of other four types 
of glucose-modified liposomes were all above 90% over 
24 hours, displaying an improved stability compared with 
the conventional liposomes.
The transendothelial ability of coumarin 
6-loaded liposomes on an in vitro  
BBB model
The BBB model in vitro was established by coculturing 
BCECs and ACs as described above to study the transend-
othelial ability of the liposomes. In order to better simulate 
the properties of BBB, we cultured BCECs on the top side 
of the membrane and the ACs on the bottom side. In the 
coculturing process, the ecphyma could extend from the ACs 
through the membrane pores to contact BCECs.
To authenticate the integrity of the model in vitro, a fluo-
rescein sodium leakage test was performed and TEER was 
measured during the whole transport process.   Fluorescein 
sodium is a fluorescent compound usually applied in the 
detection of the tight junctions of cell layers. As shown 
in Figure 2, the fluorescein sodium leakage test illustrated 
the integrity of the BBB model and the formation of the 
tight junctions. Over 6 hours in the coumarin 6-loaded 
  liposome transport study, the TEER values did not obvi-
ously reduce (.250 Ω cm2), which indicated that BBB 
barrier   properties were not disrupted during the experiment. 
As shown in Figure 3, the cumulative cleared volumes of 
GLU400-LIP, GLU1000-LIP, and GLU2000-LIP were 
higher than that of GLU200-LIP (P , 0.05) and significantly 
higher than that of the conventional liposome (P , 0.001). 
The cumulative cleared volumes of GLU400-LIP, GLU1000-
LIP, and GLU2000-LIP were 1.47, 1.39, and 1.45 times 
higher than that of GLU200-LIP, and 8.10, 7.64, and 7.95 
times higher than that of LIP, respectively. That result indi-
cated that glucose-modified liposomes linked by PEGs with 
longer chain length can promote the drug transport across 
the BBB barrier. Besides, the transporting process exhibited 
a time-dependent manner.
Biodistribution in vivo
In vivo and ex vivo NIR fluorescence imaging
Recently, NIR fluorescence imaging has been employed 
widely as a potential tool for qualitative analysis.27,28 Light 
penetrates relatively deeply into the tissue in the NIR wave-
length range of 700–900 nm. NIR fluorescence imaging 
has many advantages such as nonradioactivity and high 
Figure 1 The variation in transmittancy versus the different incubation time of 
liposomes at the wavelength of 750 nm when incubated with phosphate-buffered 
saline containing 10% (v/v) fetal bovine serum for 24 hours at 37°C (n = 3).
Abbreviations: gLU, glucose; LIP, liposomes.
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  sensitivity compared with conventional imaging methods.29,30 
A NIR fluorescence probe DIR was encapsulated in each 
liposome to trace the liposome behavior in mice. As shown 
in Figure 4, the signal intensity in the brain of GLU1000-LIP 
at each time point was all stronger than those of the other 
groups, which indicated a better brain-targeted property of 
GLU1000-LIP. As shown in Figure 5, there were NIR fluo-
rescence signals in the excised mouse brains of each group, 
and the intensity of GLU1000-LIP was the strongest among 
all the other groups, indicating an increase in the delivery of 
drug to the brain. Control animals injected with saline solu-
tion produced no background signal, which confirms that the 
observed fluorescence signal was truly from the liposome.
Confocal laser scanning microscopy
To visualize the ability of the liposomes to transport drug 
across the BBB barrier into the brain tissues, the frozen sec-
tions of mice brains were prepared and imaged accordingly. 
As shown in Figure 6, GLU1000-LIP revealed the highest 
accumulation of drug in the brains among all the other groups, 
validating that GLU1000-LIP had a more significant targeting 
contribution to the delivery of the drug into the brain.
Quantitative biodistribution study
To further evaluate the brain-targeted properties of LIP, 
GLU200-LIP, GLU400-LIP, GLU1000-LIP, and GLU2000-
LIP, in vivo distribution in mice was studied quantitatively. 
Coumarin 6 in different tissues could be completely sepa-
rated and detected using the selected analytical method. 
For brains, hearts, livers, spleens, lungs, and kidneys, the 
standard curves were y = 0.006 × −0.005 (0.5–100 ng/mL), 
y = 0.011 × −0.013 (0.1–500 ng/mL), y = 0.024 × −2.267 
(2–15,000 ng/mL), y = 0.015 × +0.017 (0.5–1000 ng/mL), 
y = 0.009 × +0.493 (1–2000 ng/mL), and y = 0.007 × +0.034 
(5–500 ng/mL), respectively, where y represents the area ratio 
(coumarin 6/coumarin 7) and x represented the concentra-
tion of coumarin 6 (ng/mL). R2 remained above 0.997 for 
all the standard curves, and the recoveries were all between 
80%–120%. In addition, the within-day precisions and 
between-day precisions were 4% and 8%, respectively. As 
shown in Figure 7, 1 hour after the intravenous injection, the 
accumulation of GLU1000-LIP in the brains were 3.93, 2.85, 
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Figure  3  The  accumulated  cleared  volumes  of  different  coumarin  6-loaded 
liposomes on the blood–brain barrier model in vitro (n = 3).
Abbreviations: gLU, glucose; LIP, liposomes.
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Figure 4 In vivo imaging of the mice that were anesthetized at 2 hours, 6 hours, and 12 hours after intravenous injection of different DIR-loaded liposomes respectively. 
Notes: Color bar indicates the intensity of the nearinfrared fluorescence signal.
Abbreviations: DIR, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine; gLU, glucose; LIP, liposomes.
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LIP Blank GLU200-LIP GLU400-LIP GLU1000-LIP GLU2000-LIP
30.00 60.00 90.00 120.00 150.00
Figure 5 Ex vivo imaging in the mouse brain 1 hour after the intravenous injection of different DIR-loaded liposomes. 
Note: The nearinfrared fluorescence signal intensity is weaker towards the left and stronger towards the right.
Abbreviations: DIR, 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindotricarbocyanine; gLU, glucose; LIP, liposomes.
LIP GLU200-LIP GLU400-LIP GLU1000-LIP GLU2000-LIP
Figure 6 Confocal laser scanning microscopy images of the mouse brain frozen sections 1 hour after the intravenous injection of different coumarin 6-loaded liposomes. 
Note: The scale bar is 75 µm on the lower right corner in each image.
Abbreviations: gLU, glucose; LIP, liposomes.
2.40, and 1.79 times higher than those of LIP, GLU200-LIP, 
GLU400-LIP, and GLU2000-LIP, respectively, which indi-
cates a more pronounced targeting efficiency for GLU1000-
LIP in brain delivery.
Discussion
Utilization of the carrier systems expressed on the BBB has 
been an attractive strategy for therapeutic delivery of drugs 
into the brain, and several carrier-mediated brain-targeting 
drug-delivery systems have been developed. Particulate 
drug-delivery systems (such as liposomes and nanoparticles) 
have been investigated extensively to increase the targeting 
efficiency of drugs to the brain through the specific endog-
enous transporters localized on the BBB interacting with 
the specific ligands modified on the surface of the delivery 
systems.31,32 In this study, we developed a brain-targeted 
liposomal system by covalently conjugating cholesterol with 
glucose, as glucose could be transported by GLUTs on the 
BBB to reach the action site in the brain.
Liposomes modified by PEGs as the linker between the 
glucose and the cholesterol obtain long-circulating properties 
by avoiding the RES effect and decreasing accumulation in 
the liver and spleen. PEGs also enhanced the chemical stabil-
ity of the liposomes in serum, and have been applied widely 
and studied extensively. In bioconjugation modification, PEG 
has been used repeatedly as a linker by providing functional 
groups required for conjugation.33 PEG remains as a spacer 
arm between liposome and conjugated antibody/protein, 
and the chain length as well as its density could influence 
the characteristics of the modified vehicles.33 End-grafted 
polymer layers assume uniform chain stretching, where all 
chain ends are located at the outer brush edge34 and could 
be conjugated with ligand for targeting purposes; in our 
case it was glucose. Therefore, a PEG spacer long enough 
to ensure the sufficient exposure of the ligands on the lipo-
some is of great importance. On the other hand, PEGs with 
a chain length that is too long are more flexible and tend 
to fold together, which could also reduce the exposure of 
the ligands. Also, the steric hindrance could take effect and 
block the interactions between liposomes and targeted sites. 
To maintain this subtle balance and obtain the optimum for-
mulation, modifications of PEGs with different chain lengths 
were designed and investigated.
PEGylation and ligand-modification were often performed 
on phospholipids which served as one of the components in 
the liposomes. Another important component is cholesterol. 
  However, it has always being neglected as an alternative anchor. 
Cholesterol as an anchor may own some merits compared 
with 1,2-dioctadecanoyl-sn-glycero-3-  phosphoethanolamine 
(DSPE). Firstly, DSPE covalently conjugated to certain 
ligands would introduce a negative charge to the liposome 
surface, thus inducing additional plasma   protein-binding. 
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Figure 7 (Continued)
In contrast, cholesterol, as an   alternative anchor, is electrically 
neutral. Secondly, the DSPE molecule is not as chemically 
stable as cholesterol and has the tendency to degrade during 
storage and application. Thirdly, the cost of DSPE is more 
than 100 times higher than that of cholesterol, which is less 
desirable for product development. The replacement of DSPE 
with cholesterol is potentially more practical.35
Particle size plays a critical role in their clearance by the 
sinusoidal spleens of human and rats. Particles must be small 
enough to avoid the splenic filtration process at the inter-
endothelial cell slits (IES) in the walls of venous sinuses.36 
Similarly, particle size is an important factor that affects 
the liposome endocytosis by the brain capillary cells on the 
BBB, and the size distribution is generally limited within 
200 nm in diameter for brain-targeted liposomes.37 In our 
study, the sizes of the prepared liposomes were all below 
170 nm, which provided a favorable size condition for brain 
transport. The particle sizes decreased due to the stabilizing 
effect of PEGs which hindered the liposome interactions. 
The PDIs increased with the introduction of PEGs, which 
can be explained by the greater flexibility and folding of 
longer chains.38 In our study, PDIs less than 0.300 and 
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Figure 7 The distributions in different organs 1 hour after the intravenous injection of different coumarin 6-loaded liposomes (n = 3).
Notes: *P , 0.05 compared with LIP; **P , 0.01 compared with LIP; ***P , 0.001. compared with LIP.
Abbreviations: gLU, glucose; LIP, liposomes.
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  particle   diameters within 200 nm were considered adequate 
for further in vitro and in vivo studies.39,40,42
After intravenous injection, the formulation could adsorb 
onto the plasma protein to form large particles. The large 
particles can be taken up by the RES readily, impeding the 
sufficient delivery of the formulation to the action site. The 
stabilities of LIP, GLU200-LIP, GLU400-LIP, GLU1000-
LIP, and GLU2000-LIP were investigated to evaluate the 
possibility of the formulations reaching the targeted site. 
The transmittancy of each sample incubated with 10% 
FBS was detected at different time points during a total of 
24 hours. The variations in the transmittances of the four 
PEG-modified glucose-linked liposomes (GLU200-LIP, 
GLU400-LIP, GLU1000-LIP, and GLU2000-LIP) were not 
as significant as the conventional group (LIP). No drastic 
increase in turbidity suggested that these formulations 
might not generate a large aggregate in bloodstream and 
could maintain their stabilities in vivo.41 On the contrary, the 
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absence of PEGs on the surface of LIP led to the formation 
of conglomeration and an reduction of the transmittance. 
Also, the absolute value of the zeta-potential of LIP increased 
without the sheltering of PEG chain coatings, contributing 
to its decreased stability.
Tight junctions between the BCECs play an important role 
in maintaining the barrier properties of the BBB in vitro. The 
results of the fluorescein sodium leakage test certified the reli-
ability and integrity of the BBB model in vitro.   Furthermore, the 
TEER value of the coculture remained above 250 Ω cm2 from 
the beginning to the end during the experiment, which indicated 
that the liposome transport did not violate the integrity of the 
BBB barrier.43 As illustrated in Figure 3, the results showed 
that the uptake of GLU400-LIP, GLU1000-LIP, and GLU2000-
LIP was more efficient than that of GLU200-LIP by the BBB 
in vitro, and the transendothelial abilities of the four types of 
glucose-modified liposomes were all much stronger than that 
of LIP, which is evidence that glucose-modification and lon-
ger PEGs could promote the liposome to transport across the 
BBB. The results also confirmed that PEGs with shorter chain 
length (PEG 200) may obstruct the exposure of the glucose. 
Liposomes modified with longer PEGs (PEG400, PEG1000, 
and PEG2000) displayed similar profiles on the in vitro BBB 
models. This might be because the in vitro BBB model can-
not entirely imitate in vivo conditions, so the long-circulating 
effects of PEG-modified liposomes did not differ from each 
other. Due to the sophistication of in vivo environments and 
to further confirm the behaviors of different formulations upon 
entering the circulation, in vivo experiments were conducted to 
determine the influences of PEGs with different chain lengths 
on the delivery properties of the liposomes.
The ex vivo and in vivo NIR fluorescent imaging and 
quantitative biodistribution study could reveal the brain-
targeted properties of each formulation in vivo more scien-
tifically and directly. Compared with other organs, especially 
livers and spleens, the amount of the liposomes delivered to 
the brains is not that much higher. BBB as a natural barrier 
poses a formidable hazard for the fabrication of brain-targeted 
drug-delivery systems. However, the developed formula-
tion achieved a greatly improved drug accumulation in the 
brains compared with conventional formulation. As shown 
in   Figure 7, the accumulation in the livers was   obviously 
reduced in GLU1000-LIP and GLU2000-LIP, which 
demonstrates an evident long-circulating effect endowed 
by the liposomes with longer PEGs as the linker. Also, it 
was obvious that GLU1000-LIP accumulated the most in 
the brains 1 hour after injection, which displays a stronger 
brain-targeted capacity compared with the other groups. 
Harashima and colleagues44 argued that shortening the PEG 
chain to a proper length would result in a facilitated mem-
brane fusion between the lipid envelope and the endosomal 
membrane, and they found PEG900 as the linker produced 
higher transfection efficiency than PEG2000. This conclusion 
was further supported by our study that PEG1000 (the chain 
length of which was close to PEG900) could realize the best 
targeted delivery among all the different PEG modifications 
including PEG2000 and others with shorter chain length.
Conclusion
The experimental data in vitro and in vivo indicated that 
the glucose-modified liposomes using PEGs with longer 
chain length as the linker was a promising brain-targeted 
drug-delivery system due to its high delivery efficiency 
across the BBB. Among all the experimental groups, 
GLU1000-LIP exhibited the strongest brain delivery 
efficiency, proving itself to be a potential brain-targeted 
drug-delivery system.
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